A nurse is teaching a client who is postpartum and has a new prescription for an injection of Rh_o(D) immunoglobulin. Which of the following should be included in the teaching?

Choice A rationale Rh_0(D) immunoglobulin, commonly known as RhoGAM, is an IgG anti-D antibody preparation administered to Rh-negative mothers. It works by binding to and clearing any fetal Rh-positive red blood cells that may have entered the maternal circulation, typically during delivery. This immune globulin prevents the mother's immune system from recognizing the D-antigen and initiating an immune response, thereby inhibiting the formation of endogenous anti-D antibodies which could harm future Rh-positive fetuses. Choice B rationale The primary mechanism of Rh_0(D) immunoglobulin is prophylactic inhibition of the maternal immune response, not the destruction or damage of already formed antibodies. If a woman is already sensitized and has developed anti-D antibodies, the administration of RhoGAM is largely ineffective as its role is to prevent initial sensitization by coating and removing fetal Rh-positive red blood cells, thus blocking antigen presentation to maternal B lymphocytes. Choice C rationale Rh_0(D) immunoglobulin is administered to the Rh-negative mother, not the Rh-positive newborn. The purpose is to protect future Rh-positive fetuses from the mother's potential anti-D antibodies. The drug acts within the maternal circulation to suppress the mother's immune reaction to the D-antigen; it has no direct action on the antibody formation process within the newborn infant. Choice D rationale This medication is given to the mother to prevent maternal alloimmunization, not to the newborn. The infant's Rh antibodies (if any) are typically derived from the mother (maternal alloimmunization) or are insignificant to the treatment protocol. Therefore, the drug's action of blocking antigen recognition and subsequent antibody production is focused solely on the Rh-negative maternal immune system.